STOCK TITAN

Sionna holder RA Capital at 14.3% after 3.4M sale

RA Capital and affiliated funds update their SION stake to 14.3% after significant September 2026 share sales.

(Moderate)
(Neutral)
Form Type
SCHEDULE 13D/A

Rhea-AI Filing Summary

Sionna Therapeutics, Inc. (SION) is the subject of an amended Schedule 13D/A from the RA Capital group updating their ownership position. RA Capital Management, L.P., together with related funds and accounts, reports beneficial ownership of 6,476,193 shares of common stock, representing 14.3% of the outstanding shares, based on 45,212,399 shares outstanding as of July 31, 2026.

The position is held across RA Capital Healthcare Fund, L.P., RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., a separately managed account, and vested stock options held by Dr. Joshua Resnick for RA Capital’s benefit. RA Capital has delegated voting and investment authority over these holdings and may be deemed the beneficial owner for Section 13(d) purposes, while various entities and individuals expressly disclaim beneficial ownership beyond regulatory reporting. On September 17, 2026, RA Capital Healthcare Fund, L.P. reported selling 3,415,011 shares in a block sale at $6.32 per share and 33,800 shares in open-market trades at a weighted average price of $7.46. RA Capital Nexus Fund III, L.P. had previously fallen below 5% ownership on November 17, 2025.

Positive

  • None.

Negative

  • None.

Filing Explained

The amendment reports RA Capital’s current ownership breakdown after the September 17 sales: 7.6% is held through RA Capital Healthcare Fund and 4.9% through RA Capital Nexus Fund III, leaving the latter below the 5% level covered by Schedule 13D/13G reporting.

Shares beneficially owned by RA Capital group 6,476,193 shares Beneficial ownership of Sionna Therapeutics common stock reported by all Reporting Persons
Percent of SION class owned by RA Capital group 14.3% Based on 45,212,399 shares outstanding as of July 31, 2026
Shares outstanding 45,212,399 shares Sionna Therapeutics common stock outstanding as of July 31, 2026
RA Capital Healthcare Fund holdings 3,448,812 shares (7.6%) Common stock of Sionna Therapeutics held directly by RA Capital Healthcare Fund, L.P.
RA Capital Nexus Fund III holdings 2,198,082 shares (4.9%) Common stock of Sionna Therapeutics held directly by RA Capital Nexus Fund III, L.P.
Block sale on September 17, 2026 3,415,011 shares at $6.32 per share Shares of Sionna Therapeutics sold by RA Capital Healthcare Fund, L.P.
Open market sale on September 17, 2026 33,800 shares at $7.46 average price Weighted average sale price, range $7.30–$7.68
Vested stock options 19,959 options Stock options held by Dr. Joshua Resnick for the benefit of RA Capital
beneficial owner regulatory
"may be deemed a beneficial owner, for purposes of Section 13(d)"
A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.
Schedule 13D regulatory
"statement on Schedule 13D originally filed with the Securities"
A Schedule 13D is a legal document that investors file with regulators when they buy a large enough stake in a company to potentially influence its management or decisions. It provides details about the investor’s intention, ownership stake, and plans, helping other investors understand who is gaining control and what their motives might be.
shared voting power financial
"Shared Voting Power 6,476,193.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
block sale financial
"Block Sale Fund 09/17/2026 3,415,011 6.32"
A block sale is a single large transaction in which a big shareholder or investor sells a substantial number of a company's shares at once, often arranged privately to avoid pushing the market price up or down. It matters to investors because such a concentrated sale can change who controls or influences a company, temporarily affect the stock’s price and liquidity, and may signal how large holders view the company’s outlook — like one person unloading a truckload of goods can move the local market.
open market sale financial
"Open Market Sale Fund 09/17/2026 33,800 7.46"
An open market sale is when a company or a shareholder sells shares through the regular stock market to any willing buyer, using ordinary exchange trading rather than private deals. It matters to investors because it increases the number of shares available and can push the price down or change ownership balance—think of it like someone putting extra items on a supermarket shelf for any shopper to buy, which can lower the item's price if supply suddenly grows.
investment adviser financial
"RA Capital serves as investment adviser for each of the Fund"
An investment adviser is a person or firm that professionally manages money and gives recommendations about buying, selling, or holding investments. Like a financial coach or guide, they have a legal duty to act in a client's best financial interest, so their advice, fees and potential conflicts can directly affect returns and risk — making their role important for investors who want informed, accountable help with portfolios.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much of Sionna Therapeutics (SION) does RA Capital currently report owning?

RA Capital and affiliated reporting persons report 6,476,193 shares of Sionna Therapeutics common stock, representing 14.3% of the outstanding shares, based on 45,212,399 shares outstanding as of July 31, 2026.

Which RA Capital entities hold SION shares according to this Schedule 13D/A?

Holdings are reported across RA Capital Healthcare Fund, L.P., RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., a separately managed account, and 19,959 vested stock options held by Dr. Joshua Resnick for RA Capital’s benefit.

What recent SION share sales did RA Capital Healthcare Fund report?

On September 17, 2026, RA Capital Healthcare Fund reported a block sale of 3,415,011 shares at $6.32 per share and an open market sale of 33,800 shares at a weighted average price of $7.46, within a range of $7.30–$7.68.

What percentage of SION does RA Capital Healthcare Fund, L.P. hold?

RA Capital Healthcare Fund, L.P. reports 3,448,812 shares of Sionna Therapeutics common stock, representing 7.6% of the outstanding shares, based on 45,212,399 shares outstanding as of July 31, 2026.

When did RA Capital Nexus Fund III, L.P. fall below 5% ownership of SION?

RA Capital Nexus Fund III, L.P. states that it ceased to be the beneficial owner of more than 5.0% of Sionna Therapeutics common stock on November 17, 2025.

Who has voting and investment power over the SION shares reported by RA Capital?

RA Capital Management, L.P. has sole power to vote and dispose of securities held in the portfolios of the Fund, Nexus Fund, Nexus Fund III, and the separately managed account. The funds have delegated this authority and disclaim beneficial ownership for Section 13(d) purposes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates





829401108

(CUSIP Number)
Peter Kolchinsky
RA Capital Management, L.P., 200 Berkeley Street, 18th Floor
Boston, MA, 02116
617.778.2500

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
09/17/2026

(Date of Event Which Requires Filing of This Statement)


If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




schemaVersion:


SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D


RA Capital Management, L.P.
Signature:/s/ Peter Kolchinsky
Name/Title:By Peter Kolchinsky, Authorized Signatory
Date:09/21/2026
Peter Kolchinsky
Signature:/s/ Peter Kolchinsky
Name/Title:Peter Kolchinsky
Date:09/21/2026
Rajeev Shah
Signature:/s/ Rajeev Shah
Name/Title:Rajeev Shah
Date:09/21/2026
RA Capital Healthcare Fund, L.P.
Signature:/s/ Peter Kolchinsky
Name/Title:By RA Capital Healthcare Fund GP, LLC, its General Partner, By Peter Kolchinsky, Manager
Date:09/21/2026
RA Capital Nexus Fund III, L.P.
Signature:/s/ Peter Kolchinsky
Name/Title:By RA Capital Nexus Fund III GP, LLC, its General Partner, By Peter Kolchinsky, Manager
Date:09/21/2026

Keep reading